SIRT1 and metabolic dysfunction-associated steatotic liver disease: It has been established by Long et al. that miR-122 inhibition protects hepatocytes against lipid metabolic disorders like Non-alcoholic fatty liver disease (NAFLD) by decreasing lipogenesis and enhancing Sirt1 and AMP-activated protein kinase (AMPK) activity [14].